Global Menopausal Hormone Therapy Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Menopausal Hormone Therapy Market Research Report 2024
Menopausal hormone therapy (MHT) is a treatment that uses hormones to relieve the symptoms of menopause. Menopause is a natural process that occurs when a woman's ovaries stop producing estrogen and progesterone. This can cause a variety of symptoms, including hot flashes, night sweats, vaginal dryness, mood swings, and difficulty sleeping.
According to MRAResearch’s new survey, global Menopausal Hormone Therapy market is projected to reach US$ 35810 million in 2033, increasing from US$ 23500 million in 2022, with the CAGR of 6.1% during the period of 2023 to 2033.
The menopausal hormone therapy (MHT) market is expected to grow significantly in the coming years, driven by a number of factors, including
Rising awareness of the benefits of menopausal hormone therapyThere is a growing awareness of the benefits of menopausal hormone therapy, such as relief of menopausal symptoms, reduced risk of osteoporosis, and improved cardiovascular health. This is also driving the demand for menopausal hormone therapy.
Changing social normsSocial norms are changing around menopause, and women are becoming more open to discussing their symptoms and seeking treatment. This is also driving the demand for menopausal hormone therapy.
The North American region is expected to be the largest market for menopausal hormone therapy, followed by Europe and the Asia Pacific region. The growth of the market in the North American region is being driven by the high prevalence of menopause and the easy availability of menopausal hormone therapy products.
Overall, the menopausal hormone therapy market is expected to grow significantly in the coming years, driven by increasing population of menopausal women, rising awareness of the benefits of menopausal hormone therapy, and changing social norms.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Menopausal Hormone Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Eli Lilly
Pfizer
AbbVie
Novo Nordisk
Merck KGaA
Mylan
Bayer
Teva
Novartis
Abbott
Roche
Endo International
Ipsen
ANI Pharmaceuticals
TherapeuticsMD
Segment by Type
Estrogen
Progesterone
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Menopausal Hormone Therapy report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Menopausal Hormone Therapy market is projected to reach US$ 35810 million in 2033, increasing from US$ 23500 million in 2022, with the CAGR of 6.1% during the period of 2023 to 2033.
The menopausal hormone therapy (MHT) market is expected to grow significantly in the coming years, driven by a number of factors, including
Rising awareness of the benefits of menopausal hormone therapyThere is a growing awareness of the benefits of menopausal hormone therapy, such as relief of menopausal symptoms, reduced risk of osteoporosis, and improved cardiovascular health. This is also driving the demand for menopausal hormone therapy.
Changing social normsSocial norms are changing around menopause, and women are becoming more open to discussing their symptoms and seeking treatment. This is also driving the demand for menopausal hormone therapy.
The North American region is expected to be the largest market for menopausal hormone therapy, followed by Europe and the Asia Pacific region. The growth of the market in the North American region is being driven by the high prevalence of menopause and the easy availability of menopausal hormone therapy products.
Overall, the menopausal hormone therapy market is expected to grow significantly in the coming years, driven by increasing population of menopausal women, rising awareness of the benefits of menopausal hormone therapy, and changing social norms.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Menopausal Hormone Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Eli Lilly
Pfizer
AbbVie
Novo Nordisk
Merck KGaA
Mylan
Bayer
Teva
Novartis
Abbott
Roche
Endo International
Ipsen
ANI Pharmaceuticals
TherapeuticsMD
Segment by Type
Estrogen
Progesterone
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Menopausal Hormone Therapy report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source